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Abstract
Background: Bullous pemphigoid (BP) is a blistering skin disorder infrequent in infancy and rarely reported in
medical literature.
Case Presentation: Here we describe three cases of BP which were referred to our department in the last
15 years. Two of them developed an eruption of bullous lesions just a few days after vaccination for diphtheria, tetanus,
pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B. The third patient developed the same blistering lesions
shortly after herpetic stomatitis. In all three cases, clinical diagnosis was confirmed by histological examination
which showed subepidermal bullae with a dermal inflammatory infiltrate, and direct immunofluorescence of
perilesional skin showed linear IgG and C3 deposits along the basement membrane zone. Immunoblot assay
was positive for BP antigen 180. Treatment with oral prednisone was instituted and the lesions resolved in two
out of three patients; the third one was treated with an immunosuppressive agent (tacrolimus) and corticosteroid and
subsequently with intravenous immunoglobulin and plasmapheresis, due to an underlying complex autoimmune disease.
Conclusion: Although the mechanism of induction of BP is still unclear, the close relationship between trigger
events (immunization or viral infection) and onset of the disease arises a possible association.
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Background
Bullous pemphigoid (BP) is an autoimmune blistering
skin disorder associated with presence of tissue-bound
and circulating IgG autoantibodies directed against
hemidesmosomal proteins, called BP antigen 180 and
BP antigen 230 [1]. Bullous pemphigoid usually affects
the elderly and is rare in childhood and infancy. BP is
diagnosed on the basis of clinical, histologic and
immunologic findings [2, 3]. Among possible trigger
factors of BP, immunization and viral infections are men-
tioned in literature. Some cases of BP have been reported
soon after vaccine administration, although the immuno-
logical mechanism underneath is still unclear [4–6].
The clinical presentation of BP amongst children
differs from that seen in adults, notably in terms of
acral involvement with predominance of palmoplantar
lesions, sparing the mucosa and genital area, in children
aged less than 1 year. Unlike in adults, childhood BP has
usually a good prognosis and resolves quite rapidly after
initiation of treatment [7].
Although a clear trigger is not well established for BP,
especially in infancy, a combination of multiple factors
can be postulated. We present here 3 cases of children
younger than 2 years who were referred to our Hospital
in the last 15 years after developing BP related in time
with a previous episode of vaccination or viral infection.
Case Presentation
A previously healthy 3-month-old boy was referred to
our Hospital with a 15-day history of a blistering
eruption on his hands and feet. He received a first dose
of combined vaccination against diphtheria, tetanus,
pertussis, poliomyelitis, hepatitis B and Haemophilus
influenzae B 2 days before the onset of the bullous rash.
He had been previously treated at home with topical
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gentamicin and oral co-amoxiclavulante, without reso-
lution of the skin eruption. There was no relevant family
history for autoimmune or blistering disorders and no risk
factors during pregnancy or delivery had been identified.
Infant was breast-fed and growing normally. Clinically he
presented with blistering lesions with a prevailing acral
distribution: large vesicles and tense bullae with surround-
ing erythema were seen on the palms and soles, whereas
widespread smaller blisters on erythematous skin could be
noticed on the trunk and abdomen (Figs. 1 and 2).
Mucous membranes were not involved and other systems’
examination was unremarkable. Observations were within
normal limits and the patient was afebrile. Results of
laboratory investigations showed that the patient had
a mild eosinophilia (1.47 × 109/L, 12% of WBC count);
inflammatory markers and complement components
were normal. Bacteriology analysis of the fluid inside
blisters revealed no infections and blood virological
tests were negative. A first biopsy for histologic study
was taken from a recent vesicular lesion and showed
subepidermal blister with a mixed superficial perivascular
inflammatory infiltrate with abundant eosinophils. A sec-
ond biopsy for direct immunofluorescence (DIF) was taken
from uninvolved perilesional skin: the results of DIF
showed linear deposition of immunoglobulin G (IgG,
faint deposits) and complement component 3 (C3, in-
tense deposits) along the basement membrane zone
leading to the diagnosis of bullous pemphigoid (Fig. 3).
The immunoblot assay was positive for BP antigen 180.
Oral steroids have been started with prednisone at
1.5 mg/kg/day for ten days. Once the development of
blisters was stopped and erythema had subsided, a careful
tapering of prednisone was started, following an alternate
day scheme. Considering the severity of the disease and
the young age of infants, we started with a higher dose
than suggested in guidelines [2]. For the whole duration of
steroid treatment, the patient was subjected to a strict
follow-up: therapy was well tolerated, with no adverse
effects, as hypertension, weight gain, hyperglycemia or
other blood test alterations. Prednisone was carefully
tapered off over a 2-month period with no evidence of
disease relapse and currently the patient is still in re-
mission. Resumption of the vaccination schedule did
not induce any recurrence of the disease.
A 17-month-old girl with a history of eczema and
autoimmune enteropathy developed a blistering eruption
on her hands and feet a few days after the second dose
of hexavalent vaccination. Considering the autoimmune
disorder affecting her gut, on the recommendation of
gastroenterologists, she was treated with an immunosup-
pressive agent (tacrolimus) and corticosteroid; during a
suspension of therapy for remission of gastrointestinal
symptoms, she received the first dose of hexavalent vac-
cination at the age of 15 months with appearance of a
Fig. 1 Patient 1: widespread small blisters on erythematous skin of
the trunk and abdomen
Fig. 2 Patient 1: large vesicles and tense bullae with surrounding
erythema located in feet, with palm and sole involvement
Fig. 3 Patient 1: direct immunofluorescence showing linear deposition
of IgG along the basement membrane zone
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single blister on the back of one hand 5 days later. At
the age of 17 months 7 days after the second dose of
vaccination, she developed a bullous rash on the limbs
which subsequently spread to the whole body. Two
punch biopsies were taken, one for the histologic examin-
ation and the other for DIF, and they led to the diagnosis
of bullous pemphigoid. The girl was treated with oral
prednisone 1 mg/kg/day; as the lesions did not improve
the dose was increased to 2 mg/kg/day but still without
benefit. Subsequently she received intravenous Ig and
finally plasmapheresis (5 sessions) with full recovery
within 6 months. The patient developed over the years
an IPEX-like syndrome caused by deficiency of CD25
(IL2-RA), characterized by immunodeficiency and auto-
immunity, which was genetically confirmed. She recently
underwent a bone marrow transplant with success.
A 2-month-old girl with unremarkable family history
for bullous diseases, developed an eruption of bullous
lesions, on an erythematous base, confluent, located in
both hands and feet, with palm and sole involvement,
together with multiple ovaloid erythematous plaques,
some with vesicles, on the abdomen. Ten days before
she had been diagnosed with acute gingivostomatitis
subsequently confirmed by PCR detection of HSV-1
DNA as herpetic stomatitis. At the beginning, to avoid
bullous impetigo, the infant was managed with intra-
venous co-amoxiclavulanate. IgM antibody titer against
HSV-1 was positive and suggestive of recent infection.
A skin biopsy subsequently confirmed BP, showing sub-
epidermal blisters. A second biopsy for direct immuno-
fluorescence DIF showed linear deposits of IgG and C3
at the epidermal BMZ, confirming the diagnosis of bul-
lous pemphigoid. Immunoblot assay was positive for BP
antigen 180. The infant was managed with oral prednisone
1 mg/kg/day with rapid improvement, and she became
free of blisters after 3 weeks of treatment. Follow-up to
6 months was good.
All parents of the three reported cases provided
written informed consent to the inclusion of data con-
cerning their infants in the manuscript in compliance
with the Helsinki Declaration.
Discussion
The reported cases are presentations of bullous pem-
phigoid, the most prevalent autoimmune blistering
skin disease, presenting with tense blisters on erythematous
skin, predominantly affecting elderly people and unusual in
infancy. Bullous pemphigoid is usually a self-limiting
disease with a clinical course that may last from months
to years in adults. In childhood and infancy BP usually
responds well to conventional treatments, with a good
prognosis [8].
The etiopathogenesis of bullous pemphigoid is complex
and during recent years much has been postulated
regarding the trigger factors related to the development of
this condition, as immunizations and viral infections
[9–11]. None of our patients had a suggestive family
history for blistering skin disease and specifically their
mothers did not develop gestational pemphigoid during
pregnancy.
Here we report the case of two infants who developed
an eruption of bullous lesions just a few days after
vaccination against diphtheria, tetanus, pertussis, polio-
myelitis, hepatitis B and Haemophilus influenzae B, while
the third patient after a viral infection by HSV-1. The
latency period ranged between 2 and 10 days. A too
short interval from immunization to onset of skin lesions
could be considered an argument against the existence of
a true relationship: since IgG production begins 10–14
days post-immunization, a 2–3 day latency period would
generally be considered too short a time-frame for auto-
immune manifestations characterized by IgG deposition
to develop. Some authors anyway have suggested that cer-
tain vaccines may unmask subclinical BP by inducing a
nonspecific immune reactivation in genetically predis-
posed infants more sensitive to the stimulus [8]. Others
hypothesized that intrauterine transmitted maternal IgG
antibodies might play a role [4] but a vertical transference
of antibodies seems unlikely since in all the cases of PB re-
ported in the literature where tests on mother’s serum
were performed, circulating anti-BMZ antibodies were
not found [11]. Moreover, according to recent studies, the
trauma caused by the vaccine injection may led to Th17
cell activation with increased of IL-17 which is able to
release pro-inflammatory cytokines and proteolytic
enzymes, which may result in blister formation [12]. Fi-
nally, CD25 deficiency may be related to BP, since the
lack of CD25+ cells has been observed in bullous
pemphigoid lesions [13].
In literature some tens of cases of childhood BP have
been reported, of which about 20 have been related to
vaccine administration, but only a few occurred in in-
fants younger than 6 months of age [6, 10, 14]. Anyway,
the association of BP and vaccination could be entirely
coincidental, given that vaccination in infants is a usual
and daily practice in developed countries while cases of
BP reported in infants are really limited. The high rate
of vaccinations in the first year of life in contrast with
the low number of reported cases of BP after vaccination
makes it difficult to explain a causal relationship, even if
described cases of recurrence after a new dose of vaccin-
ation seem to reinforce the hypothesis of a causal associ-
ation [8].
Although the histopathological and immunological
features of infantile BP are indistinguishable from those
of childhood BP and adult BP, age-related differences in
regional distribution of lesions were demonstrated. A
recent study found that lesions are more likely located
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on the extremities during the first year of life [15]. For
this reason, the clinical presentation of infantile BP seems
to differ from that of childhood and adult BP, which are
characterized by tense blisters predominantly appearing
along folds in the skin on the lower abdomen, groin,
upper thighs and arms. In our cases there was no corres-
pondence between the location of the vaccine administra-
tion and the site of occurrence of the first lesions.
The diagnosis of BP in our three cases has been
confirmed with DIF studies on perilesional skin, which
showed linear deposits of IgG and/or C3 at the epidermal
BMZ [16]. To perform the DIF, frozen sections fixed in
acetone at a temperature of 4 °C were incubated with Ig
fluorescein isothiocyanate in humid chamber (IgA,IgM,C3
diluite 1/10; IgG 1/20), then rinsed in PBS and covered
with anti-fade mounting medium.
Laboratory investigations are nonspecific, while histo-
pathologic analysis shows sub-epidermal blisters. Diagnostic
findings for BP are listed in Table 1. In our cases indirect
immunofluorescence and detection of circulating autoanti-
bodies against PB antigens were not performed.
Regarding differential diagnosis, BP should be differenti-
ated from other subepidermal diseases: most of all DIF is
useful in distinguishing BP from epidermolysis bullosa
acquisita, mucous membrane pemphigoid and linear IgA
disease. Bullous lesions may also be caused by insect bites,
burns, cellulitis and contact dermatitis. Viral and bacterial
skin infections should be recognized and treated before
starting immunosuppressive therapy [7, 16].
Treatment with oral prednisone was instituted and the
lesions rapidly resolved in two out of three patients, with
suppression of inflammation and blistering typically
achieved in a period of a few weeks, after which the dose
was gradually reduced; the third one was treated with an
immunosuppressive agent (Tacrolimus) and corticoster-
oid and subsequently with intravenous immunoglobulin
and plasmapheresis, due to a complex underlying auto-
immune disease [7].
According to a Cochrane review by Kirtschig et al. oral
corticosteroid drugs are the most common treatment regi-
mens and starting doses of prednisolone of 0.75 mg/kg/day
or less seem to be adequate to control disease and reduce
the incidence and severity of adverse reactions [17].
Other treatments with reported benefit are potent topical
steroids, azathioprine, mycophenolate mofetil, dapsone,
methotrexate, cyclosporin, cyclophosphamide, plasma
exchange, as well as erythromycin and tetracycline as
monotherapy or with nicotinamide [7, 17]. There is a
small number of case reports for the use of intravenous
immunoglobulin (IVIg) [18]. Reports have also described
successful therapy of BP patients with rituximab in
treatment-refractory forms [19].
Since up to 40% of patients with BP on systemic cortico-
steroids develop severe infectious complications resulting
in hospitalization or death [20] we administered a broad-
spectrum antibiotic therapy to our 3 patients.
Conclusion
In this article we reported two infants who developed an
eruption of bullous lesions just a few days after vaccin-
ation against diphtheria, tetanus, pertussis, poliomyelitis,
hepatitis B and Haemophilus influenzae B, while the third
patient showed the same lesions after a viral infection by
HSV-1. Although the mechanism of induction is unclear,
the close relationship between trigger events and onset of
the disease suggests that there may be an association.
Treatment with oral prednisone was effective in achieving
disease control in two out of three patients; the third one
was treated with a combination of systemic corticosteroids
and Tacrolimus and subsequently with intravenous
immunoglobulin and plasmapheresis, due to a complex
underlying autoimmune disease. BP is an uncommon auto-
immune skin disorder in infancy, although recently some
cases have been reported after vaccinations or viral infec-
tions [21, 22]. In most cases it shows prominent palmo-
plantar involvement and responds well to systemic steroid
therapy, even if recognizing it promptly is important to
establish appropriate treatment and prevent infectious
complications which may be common and severe. More
research will in fact be necessary to refine and further
elaborate our knowledge on right trigger events of BP
in infants.
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Table 1 Diagnostic findings for BP
Clinic Blistering lesions on erythematous skin,
with a prevailing acral distribution








BP antibodies deposited primarily
at the epidermal side of the
induced blister
ELISA Presence of circulating antibodies
against the 2 BP antigens (BP180
and BP230)
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